Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI
A legfontosabb adatok
- Ki végzi
- S.Biomedics Co., Ltd.
- Hol
- Dél-Korea2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 5 fő, tervezett
- Kezdés
- 2021. szept. 23.
- Várható befejezés
- 2030. szept.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Neural precursor cells derived from human embryonic stem cell line
- A regiszteradat frissítve
- 2025. május 18.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a recent, complete spinal cord injury in the neck (C4 to C7). They would receive nerve precursor cells made from a human embryonic stem cell line.
- Életkor
- 18 to 65 years
- Nem
- All sexes
- A betegség stádiuma
- Sub-acute spinal cord injury: the cells must be given on Day 7 to 60 after the injury. The injury must be complete (AIS-A) at spinal level C4-C7.
- Korábbi kezelés
- People who have had cell treatments before cannot join. Blood transfusions are allowed.
A részvétel fő kizáró okai
- Injury caused by a penetrating wound, such as a gunshot or stab wound, or a spinal cord that is fully cut through
- Several injured areas, or an injury longer than 2 cm (0,8 in) on MRI
- History of cancer, weak immune system, active infection, hepatitis B or C, or HIV
- Known allergy to basiliximab, tacrolimus, mycophenolate mofetil, methylprednisolone or prednisone
- Cannot have general anesthesia or physical therapy
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Upon written consent of the patient or the legally acceptable representative of the patient
- Male and female patients 18 to 65 years of age
- Female patients who showed negative results on the pregnancy test, use an acceptable contraceptive or have no possibility of pregnancy (at least 2 years have elapsed after menopause or have undergone hysterectomy, ovariectomy, or sterilization operation), or male patients who have received vasectomy or are willing to use contraceptives for up to 90 days after administration of the investigational product using a dual contraceptive method*; *Dual contraceptive method: Method of using multiple contraceptives, such as using a cervical cap or contraceptive diaphragm in addition to a condom for males
- Patients who are capable of being administered with the investigational product on Day 7 to 60 after spinal cord injury
- Patients who have been confirmed to have spinal cord injury classified as AIS-A on ISNCSCI, SCIM and/or MRI by the investigator, physiatrist, or other spinal cord injury specialist
- Patients whose ASIA Impairment Scale (AIS) satisfies AIS-A criteria (spinal segment within C4-C7, complete injury)
Ki nem vehet részt
- Patients incapable of receiving physical therapy or combination therapy
- Patients with other complications, including neurological defects related to peripheral nerve injury (neuromuscular injury or central spinal cord syndrome), or etiological causes of paraplegia or sensorimotor defects related to an additional underlying condition
- Patients with known hypersensitivity to basiliximab, tacrolimus, mycophenolate mofetil, methylprednisolone, or prednisone
- Patients with the following intercurrent diseases or conditions:; Coagulopathy with INR> 1.4 at the time of administration of the investigational product (Day 0); Active infection; Active hypotension requiring vasoconstrictor treatment (less than 60 mmHg of diastolic blood pressure); Rupture of the skin on the area of surgery; Medical history of malignant tumor; Primary or secondary immunodeficiency; Clinically significant abnormal values discovered as a result of laboratory tests; Creatinine > 1.5 mg/dL; When the level found in the liver-function examination is more than twice the upper limit of the normal level; Hematocrit/hemoglobin <30%/10 g/dL; Total WBC < 1000/μL; Uncontrolled hypertension (systole> 180 mmHg or diastole> 100 mmHg); Uncontrolled diabetes (HbA1c> 8%); Evidence of GI bleeding on the stool guaiac test; Positive on tuberculosis test (However, a chest X-ray may be performed if found positive on the TB test, and the patient may be enrolled upon no findings that suggest active tuberculosis on the chest X-ray.); Hepatitis B or C; Human Immunodeficiency Virus (HIV); Substance abuse or alcoholism; Unstable or untreated psychiatric disorder
- Patients with spinal cord injury caused by penetrating trauma such as gunshot or stab wounds
- Patients with complete transection on the spinal cord
- Patients with spinal cord injury that require more than the mono-segment treatment
- Patients with multiple lesions or lesions longer than 2 cm in length found on MRI examination
- Patients administered with cells excluding blood transfusion before participating in the clinical study
- Patients incapable of going under general anesthesia due to other reasons
- Patients judged unsuitable for participation in this clinical study by the investigator
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Dél-Korea.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.
A vizsgálat csoportja
- PSA-NCAM(+) NPCA vizsgált kezelés
Cells are administered through intrathecal injection. Injection is administered to a total of five areas.
Kezelés: Neural precursor cells derived from human embryonic stem cell line
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT04812431: ki vehet részt
- A regiszteradat frissítve
- 2025. május 18.